



# The use of red cell genotyping in the management of sickle cell disease

Dr Sara Trompeter – Consultant Haematologist  
UCLH and NHSBT

Dr Keir Pickard – Core Medical Trainee  
UCLH

British Blood Transfusion Society Annual Conference  
22 September 2016



## Content

- What is sickle cell disease?
- What is the role of blood transfusion in sickle cell disease?
- Why should we genotype recipients?
- Why should we genotype donors?
- Audit
- Summary




## What is sickle cell disease?

- A group of autosomal recessive disorders
- Mostly in people of African/Arab/South Asian/Southern Mediterranean descent
- Can present early in life
- Red cells will sickle and become activated and activate other cells and the endothelium
- The rate can increase – these are called crises



# What is sickle cell disease?



- HbSS
- HbSC
- HbSD
- HbSHPFH
- HbSO Arab
- HbS $\beta^+$  thalassaemia.
- HbS $\beta^0$  thalassaemia.



# What is sickle cell disease?

- Acute problems:
  - Infection, sequestration, worsening anaemia, vaso-occlusion (stroke, pain, priapism)





## What is sickle cell disease?

- Long term problems:
  - Any organ damage
    - Renal
    - Pulmonary hypertension
    - Hepatic
    - bone



## What is the role of blood transfusion in sickle cell disease?

- To correct a severe or sudden anaemia
- To reduce the proportion of sickle containing cells to either:
  - Treat a complication
  - Prevent a complication
- >90% of adults with SCD have had a transfusion at some point



# How is blood given in sickle cell disease?


- Simple top up transfusion
  - Common in childhood
  - Easy to give but leads to iron loading if given long term





## Manual exchange

Rarely given but good in an emergency as not many resources needed and can reduce sickle percentage relatively simply, some iron loading if long term





## Automated exchange

Quick,  
efficient,  
controlled, kit  
expensive and  
skills needed  
but less iron  
loading





## Automated exchange








## Why genotype patients

- Why do we need to know all the red cell antigens anyway?
- What does genotyping offer over phenotyping?



## Why do we need to know the antigen status?

- Guidelines recommend
  - matching for full Rh and Kell- can reduced alloimmunisation by 90%
  - Testing full red cell pheno/genotype up front at diagnosis
- Rh groups of patients differ from the donor cohort significantly
- Alloimmunisation common
- Blood may be needed in an emergency



copyright sara trompeter 2016



## Why do we need to know the antigen status

- Patients often transfused out of hours by non haematologists in hospitals that don't know them
- SHOT reports highlight the catastrophic nature of alloimmunisation in this cohort
- Having a central resource with antigen status fully known is a good thing

# blood

2013 122: 1062-1071  
Prepublished online May 30, 2013;  
doi:10.1182/blood-2013-03-490623

## High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors

Stella T. Chou, Tannoa Jackson, Sunitha Vege, Kim Smith-Whitley, David F. Friedman and Connie M. Westhoff

---

Updated information and services can be found at:

<http://bloodjournal.hematologylibrary.org/content/122/6/1062.full.html>

Articles on similar topics can be found in the following Blood collections

- [Free Research Articles](#) (1911 articles)
- [Red Cells, Iron, and Erythropoiesis](#) (470 articles)
- [Sickle Cell Disease](#) (75 articles)
- [Transfusion Medicine](#) (242 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:

[http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub\\_requests](http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:

<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>





## What does genotyping offer over phenotyping?

- Can test for Rh variants
- Can be done if recently transfused
- Can test for unusual antigens if little antibody available
- Data kept centrally on Haematos and accessed through SpiCE



# Haemoglobinopathy Genotyping Project – NHSBT 2015-16

- Completely innovative initiative
- Free red cell genotyping for all haemoglobinopathy patients including variants
- Shared on haemotos so can be seen when taken to other hospitals/move centre of care
- >4000 patients had their blood tested



# What about the donors?

## Efficient accurate and timely provision of blood

- Current mechanism of blood ordering
- Ability of Pulse to filter orders
- OTIF (on time in full)



## OTIF and Ro improvement project

- Initial work at UCLH 2013 orders on OBOS for sickle and thalassaemia patients

Substitution Flag	Total no. of units	%
N	30210	78.5
Y	8278	21.5
Grand Total	38488	

- Ro improvement project – Helen Mugridge and the wider NHSBT team



# What about donors?: Cost

- RCI staff time
  - Have to locate units that may be a match and then offer extended testing at that stage on a unit
- Manual rather than automated process




# What about donors?: Meeting demand

- National Haemoglobinopathy Registry
  - 9000 patients registered (estimated 14000 in total)
  - 80% in London
  - Large expanding paediatric cohort
- Data from NCA shows
  - 1/3 of those regularly transfused are children
  - 15% of those regularly transfused have been so for >10 years
- Newborn screening programme
  - >300 children pa born with scd
  - >70% are HbSS
- Haemoglobinopathy survey
  - Adults on exchange get 10 units 6 weekly, on top up or manual exchange get 3 units 3 weekly.



## Audit – Dr Keir Pickard

- 30 patients
- 15 patients with Rh variants on the automated red cell exchange programme at UCLH
- 15 adult age and sex matched patients on the same programme who did not have red cell variants
- 6 month retrospective data for all patients



## Summary data

- 2/3 men equally distributed between groups
- Mean age 43 years
- 67% of patients had any type of antibody
- 57% alloimmunised
- 10% had an antibody to a variant





## Parameters measured

- Measures of blood use
  - Total no. of units, average no. of units per episode, no of transfusion episodes
- Measures of haemolysis
  - Bilirubin and reticulocytes
- How well the targets are met: Hb and HbS pre/post exchange
- Iron loading
  - Ferritin
- Auto/allo antibodies
- Rh phenotype
- Demographics



## Grouping: 3 groups analysed

- Those with Rh variants vs. those without
- Those with antibodies to Rh variants vs. those without
- Those with antibodies to Rh variants and/or autoantibodies vs. those without



## Statistical Analysis

- IBM SPSS v.24.0
- Independent t-test for most analyses
- Cross tabs / chi squared for non-parametric data



## 1. Variants vs. no variants

- 15 in each group
- No statistical difference in any parameter



## 2. Variants with antibodies to variants vs. those without

- 3 with variants and antibodies to those variants, 27 not
- Only significance was that of bilirubin where mean 120 vs 48mmol/l  $p=0.036$



### 3. Variants with antibodies and/or those with autoantibodies vs. not

- 8 with auto/or alloantibodies to variants ie. 8/30 patients being transfused with blood that may be antigen positive for their antibody
- No statistical significance in any analysis



## Limitations

- Cohort too small and therefore would not be able to detect clinically important differences
- Follow up period short
- Included those with poor compliance



## Plans

- To do a within patient analysis with those who are getting antigen negative blood for their Rh variants.
- Expand the cohort to use other sites for both between and within patient analysis





## Summary

- Genotyping patients is of proven use in single complicated patients or in those who are recently transfused
- Patients need a red cell phenotype/genotype available centrally
- Genotyping donors would allow a more expedited issuing of results



## Acknowledgements

- Wendy Etheridge, Kirstin Finning, Andrew Hadley, Fiona Regan and all those on the HGP initiative
- Helen Mugridge, Kirk Beard and all those on the Ro improvement project
- Those throughout NHSBT who continue to support the transfusion care of SCD patients
- UCLH apheresis team especially Sr Nancy Huntley and David Leverett



Thank you

[sara.trompeter@uclh.nhs.uk](mailto:sara.trompeter@uclh.nhs.uk)

[keir.pickard@uclh.nhs.uk](mailto:keir.pickard@uclh.nhs.uk)